Recent Quotes
My Watchlist
Indicators
Local Stocks
Local Stocks
Energy Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Ligand Pharm (NQ: LGND )

123.34 USD +1.06 (+0.87%)
Official Closing Price Updated: 6:07 PM EST, Jan 15, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Ligand Pharm

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Sermonix to Present at Boston Oncology Investor Conference on Potential for Lasofoxifene in Metastatic Breast Cancer Treatment
Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific oncology products, today announced that founder and Chief... 
From GlobeNewswire News Releases
Ligand Sells Promacta Assets and Royalty for $827 Million
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and Royalty Pharma announce the sale of Ligand’s Promacta®-related intellectual property rights licensed to Novartis, including the royalty stream on... 
From Business Wire News Releases
Detailed Research: Economic Perspectives on Twenty-First Century Fox, Acadia Healthcare, Targa Resources, WellCare Health Plans, Ligand Pharmaceuticals, and Duke Energy — What Drives Growth in Today's
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Twenty-First Century Fox,... 
From GlobeNewswire News Releases
Sermonix to Present Poster at ENDO 2019 on Lasofoxifene’s ‘Potent Anti-Tumor Activity’ in ESR1 Hormone-Resistant Breast Cancer
Biopharmaceutical company collaborated with Ben May Department for Cancer Research at University of Chicago to study efficacy of lasofoxifene 
From GlobeNewswire News Releases
Reminder: Ligand to Host Analyst Day on March 12th in New York City
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will host an Analyst Day on Tuesday, March 12, 2019 from 10:00 a.m. to 12:00 p.m. Eastern time (7:00 a.m. to 9:00 a.m. Pacific time) in New York... 
From Business Wire News Releases
Ligand Reports Fourth Quarter and Full Year 2018 Financial Results
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and 12 months ended December 31, 2018, and provided an operating forecast and program updates. Ligand... 
From Business Wire News Releases
Ligand Announces OmniAb® Partnership with Genagon Therapeutics
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide OmniAb partnership with Genagon Therapeutics AB, an immuno-oncology focused biotech located in Sweden. Under... 
From Business Wire News Releases
Ligand Announces Investment in Dianomi Therapeutics
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces closing an investment in Dianomi Therapeutics, Inc., a biopharmaceutical company focused on improving the delivery and efficacy of large and... 
From Business Wire News Releases
Consolidated Research: 2019 Summary Expectations for Micron Technology, Quidel, Ligand Pharmaceuticals, Altra Industrial Motion, USG, and Equity Lifestyle Properties — Fundamental Analysis, Key Perfor
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Micron Technology, Inc.... 
From GlobeNewswire News Releases
Bragar Eagel & Squire, P.C. is Investigating Ligand Pharmaceuticals Incorporated (LGND) on Behalf of Stockholders and Encourages LGND Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating potential claims against Ligand Pharmaceuticals Incorporated (NASDAQ: LGND). Our investigation concerns whether Ligand has violated the federal securities... 
From GlobeNewswire News Releases
Ligand Partner Seelos Therapeutics Becomes a Public Company
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner Seelos Therapeutics, Inc. (NASDAQ: SEEL) announced that it has closed a reverse merger with Apricus Biosciences, Inc. The combined company... 
From Business Wire News Releases
Seelos Therapeutics, Inc. Announces Successful Completion of its Merger with Apricus Biosciences, Inc. to Advance Late-Stage Pipeline of Products for Central Nervous System (CNS) Disorders
Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of... 
From GlobeNewswire News Releases
INVESTOR ALERT: Kirby McInerney LLP Announces an Investigation of Shareholder Claims Against Ligand Pharmaceuticals Incorporated
The law firm of Kirby McInerney LLP is investigating potential claims against Ligand Pharmaceuticals Incorporated (“Ligand” or the “Company”) (NASDAQ: LGND). This investigation concerns whether Ligand... 
From Business Wire News Releases
Bragar Eagel & Squire, P.C. is Investigating Ligand Pharmaceuticals Incorporated (LGND) on Behalf of Stockholders and Encourages LGND Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating potential claims against Ligand Pharmaceuticals Incorporated (NASDAQ: LGND). Our investigation concerns whether Ligand has violated the federal securities... 
From GlobeNewswire News Releases
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Ligand Pharmaceuticals Incorporated (LGND)
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Ligand Pharmaceuticals Incorporated ("Ligand" or the "Company") (NASDAQ: LGND).... 
From GlobeNewswire News Releases
Wolf Popper LLP Announces Investigation on Behalf of Investors in Ligand Pharmaceuticals Incorporated
Wolf Popper LLP is investigating potential securities fraud claims on behalf of investors in Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) during the period May 9, 2017 through January 14, 2019,... 
From PR Newswire
Rev. Fr. Emmanuel Lemelson Renews Call for Investigation in Alleged Accounting and Securities Fraud, SEC Failures, at Ligand Pharmaceuticals
Failure to prosecute Alleged Multi-Year Accounting and Securities Fraud at Ligand Pharmaceuticals (NASDAQ: LGND) Diminishes SEC Credibility, Warrants Investigation 
From PR Newswire
Former California Deputy Attorney General and Special Prosecutor with Johnson Fistel Launches Investigation into Ligand Pharmaceuticals; Investors Suffering Losses Encouraged to Contact Firm
Shareholder Rights Law Firm Johnson Fistel, LLP with the assistance of former California Deputy Attorney General and Special Prosecutor, Tiffany Johnson, Esq., is investigating potential claims against... 
From PR Newswire
Ligand to Report Fourth Quarter and Full Year 2018 Results on February 7th
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report fourth quarter and full year 2018 financial results on February 7, 2019. Ligand’s CEO John Higgins, President and COO... 
From Business Wire News Releases
Ligand Introduces 2019 Financial Outlook and Raises 2018 Financial Guidance
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) introduces its financial outlook for 2019. Ligand expects revenue in 2019 to be at least $212 million, with up to an additional $40 million of... 
From Business Wire News Releases
Palvella Therapeutics Announces $10 Million in Funding from Ligand Pharmaceuticals to Accelerate PTX-022 through Phase 2/3 Clinical Study in Pachyonychia Congenita
Fast Track-Designated Program Commencing Phase 2/3 Study in Q1 2019 
From GlobeNewswire News Releases
Ligand Acquires Milestone and Royalty Rights to PTX-022 from Palvella Therapeutics
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the acquisition of economic rights to PTX-022 from Palvella Therapeutics. PTX-022 is a novel, topical formulation of rapamycin currently in... 
From Business Wire News Releases
Vernalis Research, a Ligand Company, Achieves Success Milestone in Collaboration with Asahi Kasei Pharma
Vernalis Research, a Ligand Company, announced the achievement of a £1 million success milestone in its drug discovery collaboration with Asahi Kasei Pharma (AKP). 
From Business Wire News Releases
Sermonix Announces FDA Acceptance of IND Application; Will Begin Phase 2 Trial of Lasofoxifene for Targeted Treatment of Women With ESR1 Mutations in Metastatic Breast Cancer
Study, set to commence in early 2019, will evaluate activity of oral lasofoxifene versus IM fulvestrant for treatment of postmenopausal women with locally advanced or metastatic ER+/HER2- breast cancer... 
From GlobeNewswire News Releases
Detailed Research: Economic Perspectives on American Tower Corporation (REIT), Ligand Pharmaceuticals, Teva Pharmaceutical Industries, Cummins, Alexander's, and Korea Electric Power — What Drives Grow
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of American Tower... 
From GlobeNewswire News Releases
Ligand Announces OmniAb® Partnership with iMetabolic Biopharma Corporation
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide OmniAb partnership with iMetabolic Biopharma Corporation (iMBP), an early stage biopharma company located in... 
From Business Wire News Releases
Sermonix Pharmaceuticals to Present Three Posters Focused on Precision Medicine in the Treatment of Metastatic Breast Cancer at San Antonio Breast Cancer Symposium
Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific oncology products, today announced the acceptance of three... 
From GlobeNewswire News Releases
Vernalis Research, a Ligand Company, Achieves Success Milestones in Collaboration with Daiichi Sankyo
Vernalis Research, a Ligand Company, announced today that it has earned multiple success milestones under its drug discovery collaboration with Daiichi Sankyo Company, Limited (Daiichi Sankyo) that... 
From Business Wire News Releases
Ligand Reports Third Quarter 2018 Financial Results
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and nine months ended September 30, 2018, and provided an operating forecast and program updates.... 
From Business Wire News Releases
Ligand to Participate in Stephens NY Investment Conference
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that the company is scheduled to participate in Stephens NY Investment Conference in New York City. Presentation takes place on Wednesday,... 
From Business Wire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.